Table 1 Study design and baseline characteristics of efficacy trials that assessed AL and AS + AQ
Study ID | Authors | Year of study | Study duration in months | Study site | Randomization | Sample size | Days of follow-up | Parasitaemia inclusion criteria/μl | Pf- GMPD | Supervised |
|---|---|---|---|---|---|---|---|---|---|---|
TZ001_AL | Martensson et al. [31] | 2002-2003 | 4 | Zanzibar | Yes, two arms | 200 | 42 | 2,000-200,000 | 13,731 | Yes |
TZ001_ AS + AQ | Martensson et al. [31] | 2002-2003 | 4 | Zanzibar | Yes, two arms | 208 | 42 | 2,000-200,000 | 19,731 | Yes |
TZ002_AL | Mutabingwa et al. [40] | 2002-2004 | 26 | Muheza | Yes, four arms | 519 | 28 | ≥2,000 | 19,280 | No |
TZ002_ AS + AQ | Mutabingwa et al. [40] | 2002-2004 | 26 | Muheza | Yes, four arms | 515 | 28 | ≥2,000 | 18,920 | No |
TZ003_AL | Kabanywanyi et al. [39] | 2004 | 7 | Kyela | Yes, four arms | 99 | 28 | 2,000-200,000 | 43,115 | Yes |
TZ003_AS + AQ | Kabanywanyi et al. [39] | 2004 | 7 | Kilombero | Yes, four arms | 76 | 28 | 2,000-200,000 | 49,348 | Yes |
TZ004_AL | Sykes et al. [41] | 2008 | 7 | Muheza | Yes, two arms | 132 | 42 | 2,000-200,000 | 24,280** | Partial |
TZ004_AZ + AS | Sykes et al. [41] | 2008 | 7 | Muheza | Yes, two arms | 129 | 42 | 2,000-200,000 | 20,960** | Partial |
TZ005_AL | Ngasala et al. [36] | 2007-2008 | 12 | Bagamoyo | Yes, two arms | 180 | 56 | 2,000-200,000 | 41,885 | Yes |
TZ005*_AL | Ngasala et al. [36]* | 2007-2008 | 12 | Bagamoyo | Yes, two arms | 179 | 56 | 2,000-200,000 | 38,272 | No |
TZ006_AL | Ngasala et al. [37] | 2007 | 6 | Kibaha | No, single arm | 244 | 42 | NR | 19,054 | No |
TZ007_AL | Kamugisha et al. [35] | 2010-2011 | 12 | Mwanza | No, single arm | 108 | 28 | 2,000-200,000 | 5,608 | Yes |
TZ008_AL | Joseph et al. [34] | 2011 | 3 | Tabora | No, single arm | 20 | 28 | 2,000-200,000 | 39,400 | Partial |
TZ009_AL*** | Shayo et al. [38] | 2013 | 2 | Muheza | No, single arm | 88 | 28 | 250-200,000 | 18,603 | Yes |